Nothing Special   »   [go: up one dir, main page]

Lee et al., 2009 - Google Patents

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa

Lee et al., 2009

Document ID
10568755031754932699
Author
Lee C
Kuo W
Beri S
Kapre S
Joshi J
Bouveret N
LaForce F
Frasch C
Publication year
Publication venue
Vaccine

External Links

Snippet

Periodic epidemics of group A meningococcal (Mn A) meningitis continue to occur in sub- Saharan Africa. For its prevention, a Mn A polysaccharide (PS)–tetanus toxoid (TT) conjugate vaccine was developed using reductive amination of polysaccharide aldehydes …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A61K47/4833Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/569Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria

Similar Documents

Publication Publication Date Title
Lee et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa
Seeberger Discovery of semi-and fully-synthetic carbohydrate vaccines against bacterial infections using a medicinal chemistry approach: focus review
CA2223080C (en) Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2,5-anhydro-d-mannose terminal structure and conjugate vaccine thereof
CA2142981C (en) Vaccines against group c neisseria meningitidis
US9057716B2 (en) Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
WO2000033882A1 (en) A vi-repa conjugate vaccine for immunization against salmonella typhi
Gao et al. Immunoactivity of protein conjugates of carba analogues from Neisseria meningitidis a capsular polysaccharide
US20150182613A1 (en) Meningococcal And Pneumococcal Conjugate Vaccine And Method Of Using Same
Chang et al. Relevance of O-acetyl and phosphoglycerol groups for the antigenicity of Streptococcus pneumoniae serotype 18C capsular polysaccharide
Humpierre et al. Expanding the scope of Ugi multicomponent bioconjugation to produce pneumococcal multivalent glycoconjugates as vaccine candidates
Hennessey Jr et al. Lessons learned and future challenges in the design and manufacture of glycoconjugate vaccines
Pawlowski et al. Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies
Guttormsen et al. Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching
US8202520B2 (en) Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
US5738855A (en) Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide
Gudlavalleti et al. Comparison of Neisseria meningitidis serogroup W135 polysaccharide–tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide
Yu et al. The Pneumococcal Polysaccharide‐Tetanus Toxin Native C‐Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity
Cuello et al. New meningococcal C polysaccharide-tetanus toxoid conjugate: Physico-chemical and immunological characterization
AU767047B2 (en) Vaccines against (escherichia coli) O157 infection
US7527797B1 (en) Vibrio cholerae 0139 conjugate vaccines
Liao et al. Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi
Hosseini et al. Evaluation of PRP anti body Haemophilus influenza type b (Hib) response with carrier protein by ELISA